口腔乾燥症治療藥市場 - 成長，趨勢，及預測(2019年 - 2024年)
Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||871437|
|出版日期||內容資訊||英文 117 Pages
|口腔乾燥症治療藥市場 - 成長，趨勢，及預測(2019年 - 2024年) Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年06月01日||內容資訊: 英文 117 Pages||
Factors such as the increase in radiation therapy and chemotherapy would lead to an increased incidence of xerostomia, acting as a major driver for the xerostomia therapeutics market. Other factors driving the market growth are increasing usage of prescription medicines, easy availability and cost-effectiveness of medicines, rising geriatric population base and increasing prevalence of diseases, such as Sjogren's syndrome, HIV, diabetes, Alzheimer's disease, and other diseases. Further, lack of awareness, unavailability of effective treatment may hinder the usage of xerostomia therapeutics products and can act as a restraining factor for the xerostomia therapeutics market.
Xerostomia is defined as dry mouth, resulting from reduced or absent saliva flow. It is not a disease, but it could be a symptom of various medical conditions, a side effect of radiation to the head and neck, or a side effect caused by a wide variety of medications. It may or may not be associated with the decreased salivary gland function. Xerostomia is a common complaint found often among older adults, affecting approximately 20% of the elderly.
Artificial Saliva Segment dominates the Market
The reduction of saliva in the mouth can lead to tooth decay, mouth infections, an altered sense of taste or smell, difficulty swallowing, pain, and many other complications. Artificial saliva is a liquid or aerosol products that are sprayed into the mouth. They are designed to moisten and relieve the pain and discomfort from chronic dry mouth, especially with regular use. While researchers are not currently able to perfectly replicate the complex chemical and physical structure of natural saliva, artificial saliva products typically do contain buffering agents, cellulose derivatives, and other elements that help temporarily promote moisture. While many artificial saliva sprays and gels claim to work for up to two hours, many users require more frequent applications to maintain moisture in the mouth, which can greatly interfere with a good night's sleep and daily activity. This also results in a greater financial expense compared to more cost-effective alternatives. Many saliva sprays and gels also have a reputation for strong and unpleasant flavors, though a recent increase in the use of naturally sweet xylitol has led to more tasteful alternatives. However, due to the increasing disease prevalence, availability of over-the-counter artificial saliva products, and the ease of application of artificial saliva, the segment is expected to register steady growth during the forecast period.
Asia Pacific Region is the Fastest Growing Region
Asia Pacific is expected to grow with a lucrative CAGR over the forecast period due to growing healthcare expenditure, increase in initiatives for raising awareness, and rising prevalence of diseases such as diabetes, HIV, cancer, & Parkinson's disease that cause dry mouth conditions. Cancer rates are increasing drastically in Asia Pacific region, with rising incomes and better access to childhood vaccinations people are living longer, which is leading to longer exposure to behavioral risk factors and the latter may lead to cancer. Emerging economies such as China and India have adopted both health and industrial policy for encouraging domestic production of cancer drugs, which is leading to lower therapy costs. Lower therapy costs, coupled with increasing awareness about cancer, and is leading to higher adoption of chemotherapy and radiotherapy.
Key players in Xerostomia (Dry Mouth Disease) Therapeutics Market are focusing on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. Some of the key players dominating the xerostomia therapeutics market are Acacia Pharma Group PLC, Church & Dwight Co. Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, OraCoat, Parnell Pharmaceuticals Inc., Pendopharm, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Synedgen among others. Key developments in Xerostomia (Dry Mouth Disease) Therapeutics Market include, in May 2018: Prisyna, the oral care division of Synedgen, received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn™ products designed to treat xerostomia.